{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:25:07Z","timestamp":1793413507426,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41375-025-02586-7","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:31:07Z","timestamp":1744147867000},"page":"1547-1557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-928X","authenticated-orcid":false,"given":"Livio","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-2466","authenticated-orcid":false,"given":"Georg","family":"Maschmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1023-5597","authenticated-orcid":false,"given":"Frederic","family":"Lamoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-7882","authenticated-orcid":false,"given":"Ola","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-989X","authenticated-orcid":false,"given":"Alienor","family":"Xhaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7728-904X","authenticated-orcid":false,"given":"Manuela","family":"Spadea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-5613","authenticated-orcid":false,"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-5470","authenticated-orcid":false,"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of ECIL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Aguilar","family":"Guisado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Akova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Averbuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Baccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Calandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Compagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"De La Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thushan","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Nuno Direito","family":"de Morais Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Galaverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Garcia","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Eivind Leren","family":"Myrhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Oltolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Pinana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Reigadas","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Sadowska-Klasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Spadea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Vanbiervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2586_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejcsup.2007.06.001","volume":"5","author":"C Cordonnier","year":"2007","unstructured":"Cordonnier C, Calandra T. The first European Conference on Infections in Leukaemia: why and how?. Eur J Cancer. 2007;5:2\u20134\u20134.","journal-title":"Eur J Cancer"},{"key":"2586_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejcsup.2007.06.006","volume":"5","author":"JA Maertens","year":"2007","unstructured":"Maertens JA, Fr\u00e8re P, Lass-Fl\u00f6rl C, Heinz W, Cornely OA. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer. 2007;5:43\u201348\u20138.","journal-title":"Eur J Cancer"},{"key":"2586_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bmt.2010.175","volume":"46","author":"J Maertens","year":"2011","unstructured":"Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fl\u00fcckiger U, Fr\u00eare P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update. Bone Marrow Transpl. 2011;46:709\u201318.","journal-title":"Bone Marrow Transpl"},{"key":"2586_CR4","first-page":"3221","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from European Conference on Infections in Leukemia. J Antimicrob Chemother. 2018;73:3221\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"2586_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1469-0691.12041","volume":"18","author":"AJ Ullmann","year":"2012","unstructured":"Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18:53\u201367.","journal-title":"Clin Microbiol Infect"},{"key":"2586_CR6","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","volume":"72","author":"P Bose","year":"2021","unstructured":"Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, et al. Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study. Clin Infect Dis. 2021;72:1755\u201363.","journal-title":"Clin Infect Dis"},{"key":"2586_CR7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/cid\/ciac230","volume":"75","author":"CR Rausch","year":"2022","unstructured":"Rausch CR, DiPippo AJ, Jiang Y, DiNardo CD, Kadia T, Maiti A, et al. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis. 2022;75:1503\u201310.","journal-title":"Clin Infect Dis"},{"key":"2586_CR8","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jac\/dky550","volume":"74","author":"MI Del Principe","year":"2019","unstructured":"Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, et al. \u2018Real-life\u2019 analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. J Antimicrob Chemother. 2019;74:1062\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2586_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","volume":"36","author":"G Maschmeyer","year":"2022","unstructured":"Maschmeyer G, Bullinger L, Garcia-Vidal C, Herbrecht R, Maertens J, Menna P, et al. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia. 2022;36:1215\u201326.","journal-title":"Leukemia"},{"key":"2586_CR10","doi-asserted-by":"publisher","first-page":"e13675","DOI":"10.1111\/tid.13675","volume":"23","author":"S Kallee","year":"2021","unstructured":"Kallee S, Scharf C, Schroeder I, Paal M, Vogeser M, Irlbeck M, et al. Comparing posaconazole and itraconazole for antifungal prophylaxis in critically ill lung transplant recipients: Efficacy and plasma concentrations. Transpl Infect Dis. 2021;23:e13675.","journal-title":"Transpl Infect Dis"},{"key":"2586_CR11","doi-asserted-by":"publisher","first-page":"105886","DOI":"10.1016\/j.ijantimicag.2020.105886","volume":"55","author":"MS Copley","year":"2020","unstructured":"Copley MS, Waldron M, Athans V, Welch SC, Brizendine KD, Cober E, et al. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study. Int J Antimicrob Agents. 2020;55:105886.","journal-title":"Int J Antimicrob Agents"},{"key":"2586_CR12","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1093\/jac\/dkz303","volume":"74","author":"B Nield","year":"2019","unstructured":"Nield B, Larsen SR, van Hal SJ. Clinical experience with new formulation SUBA\u00ae-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. J Antimicrob Chemother. 2019;74:3049\u201355.","journal-title":"J Antimicrob Chemother"},{"key":"2586_CR13","doi-asserted-by":"publisher","first-page":"e13587","DOI":"10.1111\/tid.13587","volume":"23","author":"TJ Whitmore","year":"2021","unstructured":"Whitmore TJ, Yaw M, Lavender M, Musk M, Boan P, Wrobel J. A novel highly bio-available itraconazole formulation (SUBA\u00ae-Itraconazole) for anti-fungal prophylaxis in lung transplant recipients. Transpl Infect Dis. 2021;23:e13587.","journal-title":"Transpl Infect Dis"},{"key":"2586_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","volume":"77","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study. J Infect. 2018;77:227\u201334.","journal-title":"J Infect"},{"key":"2586_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/myc.13232","volume":"64","author":"SM Wingen-Heimann","year":"2021","unstructured":"Wingen-Heimann SM, Cornely OA, Vehreschild MJGT, Wisplinghoff H, Franke B, Schons M, et al. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis. Mycoses. 2021;64:437\u201344.","journal-title":"Mycoses"},{"key":"2586_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s11605-019-04241-w","volume":"24","author":"WH Kang","year":"2020","unstructured":"Kang WH, Song GW, Lee SG, Suh KS, Lee KW, Yi NJ, et al. A multicenter, randomized, open-label study to compare micafungin with fluconazole in the prophylaxis of invasive fungal infections in living-donor liver transplant recipients. J Gastrointest Surg. 2020;24:832\u201340.","journal-title":"J Gastrointest Surg"},{"key":"2586_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0140-6736(23)00874-7","volume":"402","author":"U Platzbecker","year":"2023","unstructured":"Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:327\u201385.","journal-title":"Lancet"},{"key":"2586_CR18","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00277-017-3091-x","volume":"96","author":"N Lorenzana","year":"2017","unstructured":"Lorenzana N, Avila LF, Alonso S, Colado E, Bernal T. The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment. Ann Hematol. 2017;96:1833\u201340.","journal-title":"Ann Hematol"},{"key":"2586_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ejh.13631","volume":"107","author":"A Tey","year":"2021","unstructured":"Tey A, Shaw B, Cardamone L, Shepherd S, Paul E, Rogers B, et al. Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome. Eur J Haematol. 2021;107:181\u20139.","journal-title":"Eur J Haematol"},{"key":"2586_CR20","doi-asserted-by":"publisher","first-page":"204062072096688","DOI":"10.1177\/2040620720966882","volume":"11","author":"KW Kang","year":"2020","unstructured":"Kang KW, Lee BH, Jeon MJ, Yu ES, Sik Kim D, Lee SR, et al. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. Ther Adv Hematol. 2020;11:2040620720966882.","journal-title":"Ther Adv Hematol"},{"key":"2586_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/myc.12500","volume":"59","author":"H Pomares","year":"2016","unstructured":"Pomares H, Arnan M, S\u00e1nchez-Ortega I, Sureda A, Duarte RF. Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?. Mycoses. 2016;59:516\u20139.","journal-title":"Mycoses"},{"key":"2586_CR22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00277-017-3001-2","volume":"96","author":"A Schuck","year":"2017","unstructured":"Schuck A, Goette MC, Neukirchen J, Kuendgen A, Gattermann N, Schroeder T, et al. A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Ann Hematol. 2017;96:1097\u2013104.","journal-title":"Ann Hematol"},{"key":"2586_CR23","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","volume":"58","author":"JA Trubiano","year":"2017","unstructured":"Trubiano JA, Dickinson M, Thursky KA, Spelman T, Seymour JF, Slavin MA, et al. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leuk Lymphoma. 2017;58:2379\u201386.","journal-title":"Leuk Lymphoma"},{"key":"2586_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.clml.2019.01.002","volume":"19","author":"K M\u0105dry","year":"2019","unstructured":"M\u0105dry K, Lis K, Biecek P, M\u0142ynarczyk M, Rytel J, G\u00f3rka M, et al. Predictive model for infection risk in myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia patients treated with azacitidine; azacitidine infection risk model: the polish adult leukemia group study. Clin Lymphoma Myeloma Leuk. 2019;19:264\u201374.e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2586_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hon.2710","volume":"38","author":"R Latagliata","year":"2020","unstructured":"Latagliata R, Niscola P, Fianchi L, Aloe Spiriti MA, Maurillo L, Carmosino I, et al. Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematol Oncol. 2020;38:189\u201396.","journal-title":"Hematol Oncol"},{"key":"2586_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ajh.25808","volume":"95","author":"GYG Kim","year":"2020","unstructured":"Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, et al. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. Am J Hematol. 2020;95:792\u20138.","journal-title":"Am J Hematol"},{"key":"2586_CR27","doi-asserted-by":"publisher","first-page":"107043","DOI":"10.1016\/j.leukres.2023.107043","volume":"127","author":"TA Kirkizlar","year":"2023","unstructured":"Kirkizlar TA, Kirkizlar O, Demirci U, Umut A, Iflazoglu H, Umit EG, et al. Incidence and predisposing factors of infection in patients treated with hypomethylating agents. Leuk Res. 2023;127:107043.","journal-title":"Leuk Res"},{"key":"2586_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ajh.24572","volume":"92","author":"N Polverelli","year":"2017","unstructured":"Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92:37\u201341.","journal-title":"Am J Hematol"},{"key":"2586_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41375-020-0909-7","volume":"35","author":"AR Landtblom","year":"2021","unstructured":"Landtblom AR, Andersson TM, Dickman PW, Smedby KE, Eloranta S, Batyrbekova N, et al. Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients. Leukemia. 2021;35:476\u201384.","journal-title":"Leukemia"},{"key":"2586_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00277-016-2884-7","volume":"96","author":"M Breccia","year":"2017","unstructured":"Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, et al. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Ann Hematol. 2017;96:387\u201391.","journal-title":"Ann Hematol"},{"key":"2586_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/hon.2429","volume":"36","author":"F Palandri","year":"2018","unstructured":"Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, et al. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. Hematol Oncol. 2018;36:285\u201390.","journal-title":"Hematol Oncol"},{"key":"2586_CR32","doi-asserted-by":"publisher","unstructured":"Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, et al. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematol Oncol. 2018. https:\/\/doi.org\/10.1002\/hon.2509.","DOI":"10.1002\/hon.2509"},{"key":"2586_CR33","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00277-018-3242-8","volume":"97","author":"P Sylvine","year":"2018","unstructured":"Sylvine P, Thomas S, Pirayeh E. French network of regional pharmacovigilance centers. infections associated with ruxolitinib: study in the french pharmacovigilance database. Ann Hematol. 2018;97:913\u20134.","journal-title":"Ann Hematol"},{"key":"2586_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2019.1688323","volume":"61","author":"D Tremblay","year":"2020","unstructured":"Tremblay D, King A, Li L, Moshier E, Coltoff A, Koshy A, et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2020;61:660\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2586_CR35","doi-asserted-by":"crossref","unstructured":"Stafylidis C, Diamantopoulos P, Athanasoula E, Solomou E, Anastasopoulou A. 2022. Acute lymphoblastic leukemia and invasive mold infections: a challenging field. J Fungi. 2022;8:1127.","DOI":"10.3390\/jof8111127"},{"key":"2586_CR36","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/ciab1026","volume":"75","author":"JAW Gold","year":"2022","unstructured":"Gold JAW, Tolu SS, Chiller T, Benedict K, Jackson BR. Incidence of invasive fungal infections in patients initiating ibrutinib and other small molecule kinase Inhibitors-United States, July 2016-June 2019. Clin Infect Dis. 2022;75:334\u20137.","journal-title":"Clin Infect Dis"},{"key":"2586_CR37","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"2586_CR38","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387.","journal-title":"Cancer"},{"key":"2586_CR39","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/jac\/dkr223","volume":"66","author":"RM van Schie","year":"2011","unstructured":"van Schie RM, Bruggemann RJ, Hoogerbrugge PM, te Loo DM. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother. 2011;66:1853\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"2586_CR40","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.12659\/MSM.893142","volume":"21","author":"L Yang","year":"2015","unstructured":"Yang L, Yu L, Chen X, Hu Y, Wang B. Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia. Med Sci Monit. 2015;21:1656\u201361.","journal-title":"Med Sci Monit"},{"key":"2586_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jac\/dkv343","volume":"71","author":"TN Doan","year":"2016","unstructured":"Doan TN, Kirkpatrick CM, Walker P, Slavin MA, Ananda-Rajah MR, Morrissey CO, et al. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. J Antimicrob Chemother. 2016;71:497\u2013505.","journal-title":"J Antimicrob Chemother"},{"key":"2586_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01716-2","volume":"11","author":"SM Oh","year":"2021","unstructured":"Oh SM, Byun JM, Chang E, Kang CK, Shin DY, Koh Y, et al. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis. Sci Rep. 2021;11:22160.","journal-title":"Sci Rep"},{"key":"2586_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12185-017-2342-x","volume":"107","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xing Y, Chen L, Meng T, Li Y, Xie J, et al. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis. Int J Hematol. 2018;107:235\u201343.","journal-title":"Int J Hematol"},{"key":"2586_CR44","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/jac\/dkx133","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Leguay T, Maertens J, Vehreschild M, Anagnostopoulos A, Castagnola C, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017;72:2359\u201367.","journal-title":"J Antimicrob Chemother"},{"key":"2586_CR45","doi-asserted-by":"publisher","first-page":"7629","DOI":"10.1002\/cam4.4293","volume":"10","author":"SM Infante","year":"2021","unstructured":"Infante SM, Fernandez-Cruz A, Nunez L. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer Med. 2021;10:7629\u201340.","journal-title":"Cancer Med"},{"key":"2586_CR46","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.3324\/haematol.2016.151837","volume":"102","author":"MC Tisi","year":"2017","unstructured":"Tisi MC, Hohaus S, Cuccaro A, Innocenti I, De Carolis E, Za T, et al. Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. Haematologica. 2017;102:e108\u2013e11.","journal-title":"Haematologica"},{"key":"2586_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3901-y","volume":"19","author":"JC Valentine","year":"2019","unstructured":"Valentine JC, Morrissey CO, Tacey MA, Liew D, Patil S, Peleg AY, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005-2016. BMC Infect Dis. 2019;19:274.","journal-title":"BMC Infect Dis"},{"key":"2586_CR48","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hon.2343","volume":"35","author":"A Visentin","year":"2017","unstructured":"Visentin A, Gurrieri C, Imbergamo S, Lessi F, Di Maggio SA, Frezzato F, et al. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematol Oncol. 2017;35:925\u20138.","journal-title":"Hematol Oncol"},{"key":"2586_CR49","doi-asserted-by":"publisher","first-page":"e13676","DOI":"10.1111\/myc.13676","volume":"67","author":"M Allouchery","year":"2024","unstructured":"Allouchery M, Brunet K, Tomowiak C, Singier A, Pambrun E, Pariente A, et al. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study. Mycoses. 2024;67:e13676.","journal-title":"Mycoses"},{"key":"2586_CR50","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jiac.2021.08.005","volume":"27","author":"T Holowka","year":"2021","unstructured":"Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, et al. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. J Infect Chemother. 2021;27:1700\u20135.","journal-title":"J Infect Chemother"},{"key":"2586_CR51","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/10428194.2022.2161305","volume":"64","author":"T Yasu","year":"2023","unstructured":"Yasu T, Sakurai K, Hoshino M, Akazawa M. Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study. Leuk Lymphoma. 2023;64:730\u20133.","journal-title":"Leuk Lymphoma"},{"key":"2586_CR52","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068\u201375.","journal-title":"Haematologica"},{"key":"2586_CR53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/myc.13178","volume":"64","author":"C Lim","year":"2021","unstructured":"Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study. Mycoses. 2021;64:30\u20134.","journal-title":"Mycoses"},{"key":"2586_CR54","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00277-020-04125-z","volume":"99","author":"CK Tsai","year":"2020","unstructured":"Tsai CK, Liu YC, Kuan AS, Lee KL, Yeh CM, Lee YT, et al. Risk and impact of invasive fungal infections in patients with multiple myeloma. Ann Hematol. 2020;99:1813\u201322.","journal-title":"Ann Hematol"},{"key":"2586_CR55","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136.","journal-title":"Nat Med"},{"key":"2586_CR56","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"2586_CR57","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"2586_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14:35.","journal-title":"Blood Cancer J"},{"key":"2586_CR59","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130:886\u2013900.","journal-title":"Cancer"},{"key":"2586_CR60","doi-asserted-by":"publisher","first-page":"e7048","DOI":"10.1002\/cam4.7048","volume":"13","author":"K Uttervall","year":"2024","unstructured":"Uttervall K, T\u00e4tting L, Lemonakis K, Majd M, Crafoord J, Olsson M, et al. Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden. Cancer Med. 2024;13:e7048.","journal-title":"Cancer Med"},{"key":"2586_CR61","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10:e801\u201312.","journal-title":"Lancet Haematol"},{"key":"2586_CR62","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00277-014-2093-1","volume":"93","author":"K Takaoka","year":"2014","unstructured":"Takaoka K, Nannya Y, Shinohara A, Arai S, Nakamura F, Kurokawa M. A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma. Ann Hematol. 2014;93:1637\u201344.","journal-title":"Ann Hematol"},{"key":"2586_CR63","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jiph.2024.04.005","volume":"17","author":"\u00c1 Tamayo-Velasco","year":"2024","unstructured":"Tamayo-Velasco \u00c1, L\u00f3pez-Herrero R, G\u00f3mez-Garc\u00eda LM, S\u00e1nchez-de Prada L, Aguilar-Monserrate G, Mart\u00edn-Fern\u00e1ndez M, et al. COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study. J Infect Public Health. 2024;17:939\u201346.","journal-title":"J Infect Public Health"},{"key":"2586_CR64","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41409-019-0475-7","volume":"54","author":"A Fayard","year":"2019","unstructured":"Fayard A, Daguenet E, Blaise D, Chevallier P, Labussi\u00e8re H, Berceanu A, et al. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the francophone society of stem cell transplantation and cellular therapy (SFGM-TC). Bone Marrow Transpl. 2019;54:1586\u201394.","journal-title":"Bone Marrow Transpl"},{"key":"2586_CR65","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1038\/s41409-021-01260-7","volume":"56","author":"MY Lien","year":"2021","unstructured":"Lien MY, Yeh SP, Gau JP, Wang PN, Li SS, Dai MS, et al. High rate of invasive fungal infections after non-t cell depleted haploidentical allo-HSCT even under antifungal prophylaxis. Bone Marrow Transpl. 2021;56:1750\u201353.","journal-title":"Bone Marrow Transpl"},{"key":"2586_CR66","first-page":"805514","volume":"11","author":"A Busca","year":"2021","unstructured":"Busca A, Cinatti N, Gill J, Passera R, Dellacasa CM, Giaccone L, et al. Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: the turin experience. Frontiers in Cellular and Infection. Microbiology. 2021;11:805514.","journal-title":"Microbiology"},{"key":"2586_CR67","doi-asserted-by":"publisher","first-page":"114.e1","DOI":"10.1016\/j.jtct.2023.09.017","volume":"30","author":"GA Papanicolaou","year":"2024","unstructured":"Papanicolaou GA, Chen M, He N, Martens MJ, Kim S, Batista MV, et al. \u2018Incidence and impact of fungal infections in post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis\u2019. Transpl Cell Ther. 2024;30:114.e1\u2013114.e16.","journal-title":"Transpl Cell Ther"},{"key":"2586_CR68","doi-asserted-by":"publisher","first-page":"508.e1","DOI":"10.1016\/j.jtct.2022.04.023","volume":"28","author":"JS Little","year":"2022","unstructured":"Little JS, Shapiro RM, Aleissa MM, Kim A, Chang J, Kubiak DW, et al. \u2018Invasive yeast infection after haploidentical donor hematopoietic cell transplantation associated with cytokine release syndrome\u2019. Transpl Cell Ther. 2022;28:508.e1\u2013508.e8.","journal-title":"Transpl Cell Ther"},{"key":"2586_CR69","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","volume":"26","author":"A Stern","year":"2020","unstructured":"Stern A, Su Y, Lee YJ, Seo S, Shaffer B, Tamari R, et al. A Single-center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;26:1195\u2013202.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2586_CR70","doi-asserted-by":"publisher","first-page":"ofad424","DOI":"10.1093\/ofid\/ofad424","volume":"10","author":"MH Nguyen","year":"2020","unstructured":"Nguyen MH, Ostrosky-Zeichner L, Pappas PG, Walsh TJ, Bubalo J, Alexander BD, et al. Real-World Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results from a Subgroup Analysis of a Multicenter National Registry. Open Forum Infect Dis. 2020;10:ofad424.","journal-title":"Open Forum Infect Dis"},{"key":"2586_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","volume":"27","author":"SS Dadwal","year":"2021","unstructured":"Dadwal SS, Hohl TM, Fisher CE, Boeckh M, Papanicolaou G, Carpenter PA, et al. American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. Transpl Cell Ther. 2021;27:201\u201311.","journal-title":"Transpl Cell Ther"},{"key":"2586_CR72","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","volume":"20","author":"C Girmenia","year":"2014","unstructured":"Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transpl. 2014;20:872\u201380.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2586_CR73","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood.2020005884","volume":"136","author":"P Puerta-Alcalde","year":"2020","unstructured":"Puerta-Alcalde P, Champlin RE, Kontoyiannis DP. How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. Blood. 2020;136:2741\u201353.","journal-title":"Blood"},{"key":"2586_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105:297\u2013316.","journal-title":"Haematologica"},{"key":"2586_CR75","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","volume":"54","author":"AJ Kansagra","year":"2019","unstructured":"Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical Utilization of Chimeric Antigen Receptor T-Cells (CAR-T) in B-Cell Acute Lymphoblastic Leukemia (ALL)-an Expert Opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transpl. 2019;54:1868\u201380.","journal-title":"Bone Marrow Transpl"},{"key":"2586_CR76","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/cid\/ciy152","volume":"67","author":"JH Park","year":"2018","unstructured":"Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clinical Infect Dis. 2018;67:533\u201340.","journal-title":"Clinical Infect Dis"},{"key":"2586_CR77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131:121\u201330.","journal-title":"Blood"},{"key":"2586_CR78","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","volume":"6","author":"JS Little","year":"2022","unstructured":"Little JS, Aleissa MM, Beluch K, Gonzalez-Bocco IH, Marty FM, Manne-Goehler J, et al. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor t-cell therapy for non-hodgkin lymphoma. Blood Adv. 2022;6:4821\u201330.","journal-title":"Blood Adv"},{"key":"2586_CR79","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1016\/S1473-3099(23)00563-7","volume":"24","author":"KPL Cheok","year":"2024","unstructured":"Cheok KPL, Farrow A, Springell D, O'Reilly M, Morley S, Stone N, et al. Mucormycosis after CD19 Chimeric Antigen Receptor T-Cell Therapy: Results of a US Food and Drug Administration Adverse Events Reporting System Analysis and a Review of the Literature. Lancet Infect Dis. 2024;24:e256\u201365.","journal-title":"Lancet Infect Dis"},{"key":"2586_CR80","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/jof7020156","volume":"7","author":"W Garner","year":"2021","unstructured":"Garner W, Palash S, Haidar G. Invasive fungal infections after anti-cd19 chimeric antigen receptor-modified t-cell therapy: state of the evidence and future directions. J Fungi. 2021;7:156.","journal-title":"J Fungi"},{"key":"2586_CR81","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","volume":"22","author":"AH Groll","year":"2021","unstructured":"Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA, Averbuch D, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22:e254\u201369.","journal-title":"Lancet Oncol"},{"key":"2586_CR82","first-page":"72","volume":"37","author":"T Lehrnbecher","year":"2022","unstructured":"Lehrnbecher T, Groll AH, Cesaro S, Alten J, Attarbaschi A, Barbaric D, et al. Invasive fungal diseases impact on outcome of childhood ALL \u2013 an analysis of the international trial AIEOP-BFM ALL 2009. Leuk 2022 371. 2022;37:72\u20138.","journal-title":"Leuk 2022 371"},{"key":"2586_CR83","doi-asserted-by":"crossref","unstructured":"Groll AH, Abdel-Azim H, Lehrnbecher T, Steinbach WJ, Paschke A, Mangin E, et al. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. Int J Antimicrob Agents. 2020;56:106084.","DOI":"10.1016\/j.ijantimicag.2020.106084"},{"key":"2586_CR84","doi-asserted-by":"crossref","unstructured":"Groll AH, K\u00f6rholz K, Holterhus M, Lehrnbecher T. New and emerging options for management of invasive fungal diseases in paediatric patients. Mycoses. 2024;67:e13654.","DOI":"10.1111\/myc.13654"},{"key":"2586_CR85","unstructured":"Noxafil | European Medicines Agency (EMA). Accessed November 3, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/noxafil."},{"key":"2586_CR86","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jpids\/piaa119","volume":"10","author":"CC Dvorak","year":"2021","unstructured":"Dvorak CC, Fisher BT, Esbenshade AJ, Nieder ML, Alexander S, Steinbach WJ, et al. A randomized trial of caspofungin vs triazoles prophylaxis for invasive fungal disease in pediatric allogeneic hematopoietic cell transplant. J Pediatr Infect Dis Soc. 2021;10:417\u201325.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2586_CR87","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81:1703\u201329.","journal-title":"Drugs"},{"key":"2586_CR88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson 3rd","year":"2023","unstructured":"Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401:49\u201359.","journal-title":"Lancet"},{"key":"2586_CR89","unstructured":"xxx. https:\/\/clinicaltrials.gov\/study\/NCT04368559?cond=rezafungin&rank=7."},{"key":"2586_CR90","first-page":"100245","volume":"6","author":"LW El Ayoubi","year":"2024","unstructured":"El Ayoubi LW, Allaw F, Moussa E, Kanj SS. Ibrexafungerp: A narrative overview. Curr Res Micro Sci. 2024;6:100245.","journal-title":"Curr Res Micro Sci"},{"key":"2586_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10143-3","volume":"24","author":"Y Vanbiervliet","year":"2024","unstructured":"Vanbiervliet Y, Van Nieuwenhuyse T, Aerts R, Lagrou K, Spriet I, Maertens J. Review of the novel antifungal drug olorofim (F901318). BMC Infect Dis. 2024;24. 1256.","journal-title":"BMC Infect Dis"},{"key":"2586_CR92","first-page":"e59210","volume":"16","author":"A Almajid","year":"2024","unstructured":"Almajid A, Bazroon A, Al-Awami HM, Albarbari H, Alqahtani I, Almutairi R, et al. Fosmanogepix: the novel anti-fungal agent\u2019s comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials. Cureus. 2024;16:e59210.","journal-title":"Cureus"},{"key":"2586_CR93","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/jac\/dkad269","volume":"78","author":"OA Cornely","year":"2023","unstructured":"Cornely OA, Ostermann H, Koehler P, Teschner D, Limburg E, Kramer WG, et al. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. Antimicrob Chemother. 2023;78:2645\u201352.","journal-title":"Antimicrob Chemother"},{"key":"2586_CR94","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14787210.2024.2409408","volume":"22","author":"CF Neoh","year":"2024","unstructured":"Neoh CF, Jeong W, Kong DCM, Beardsley J, Kwok P, Slavin MA, et al. New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections. Expert Rev Anti Infect Ther. 2024;22:1085\u201398.","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02586-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T03:02:52Z","timestamp":1751252572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2586"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02586-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Livio Pagano (LP) was Board member of Gilead Science, MSD, Pfizer, Menarini-Stemline, Gentili, Jazz Pharmaceutical, Cidara and has received speaker\u2019s honoraria from Gilead Sciences, Kyowa Kirin, MSD, Pfizer Pharmaceuticals, Astellas Pharma, Novartis, Jazz Pharmaceutical, Janseen-Cilag, Astra Zeneca, F2G, Abbvie. Consultant for Menarini, Cidara. Georg Maschmeyer (GM) has received speaker\u2019s honoraria from Gilead Sciences. Frederic Lamoth (FL) reports research funding from Gilead, MSD, Pfizer and Novartis, and honoraria for conferences or advisory boards from Gilead, MSD, Pfizer, Mundipharma and Becton-Dickinson, outside of the submitted work. All contracts were made with and fees paid to his institution (CHUV). Ola Blennow has received speaker\u2019s honoraria from Gilead Sciences. Alienor Xhaard (AX) has received speaker\u2019s honoraria from Merck Sharp and Dohme and Pfizer Pharmaceuticals. Manuela spadea (MS) nothing to declare. Alessandro Busca (AB) was Board member of Gilead Science, Takeda, and has received speaker\u2019s honoraria from Gilead Kite Sciences, MSD, Pfizer Pharmaceuticals, Novartis, Jazz Pharmaceutical, Astra-Zeneca, Abbvie, Menarini Stemline, Takeda. Catherine Cordonnier (CC) has received speaker\u2019s honoraria from Gilead Science and MSD, and consulting fees from Cidara and Mundipharma. Johan Maertens (JM) reports consulting fees from Amplyx, Cidara, Gilead, Pfizer, Scynexis, F2G, Mundipharma, Takeda, and Basilea; Honoraria for lectures from Astellas, Gilead, Basilea, Mundipharma, Takeda, MedScape, Pfizer, and Shionogi; Participation on Advisory Board from Cidara, Pulmocide, Shionogi, Basilea, Sfunga.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Livio Pagano, Georg Maschmeyer, Frederic Lamoth, Ola Blennow, Alienor Xhaard, Manuela Spadea, Alessandro Busca, Catherine Cordonnier, Johan Maertens.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ECIL members who participated in the drafting of these recommendations"}}]}}